Replies to post #212416 on Biotech Values

[DewDiligence]

MNTA—Do you know the hold up with M254?

I don't think there is a holdup per se. Rather, MNTA prioritized M230 due to the partnership with CSL (announced in Jan 2017, but clearly in the works during 2016) and M281, which Craig Wheeler considers MNTA's most promising new-drug candidate.